Your browser doesn't support javascript.
loading
Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder.
Zimmermann, Heiner; Weiland, Theresa; Nourse, Jamie P; Gandhi, Maher K; Reinke, Petra; Neuhaus, Ruth; Karbasiyan, Mohsen; Gärtner, Barbara; Anagnostopoulos, Ioannis; Riess, Hanno; Trappe, Ralf U; Oertel, Stephan.
Afiliação
  • Zimmermann H; Department of Internal Medicine II: Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany.
  • Weiland T; Department of Hematology, Charite University Hospitals, Campus Virchow-Klinikum, 13353 Berlin, Germany.
  • Nourse JP; Clinical Immunohaematology Laboratory, Queensland Institute of Medical Research, Brisbane QLD 4006, Australia.
  • Gandhi MK; Clinical Immunohaematology Laboratory, Queensland Institute of Medical Research, Brisbane QLD 4006, Australia.
  • Reinke P; Department of Nephrology and Intensive Care, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, 13353 Berlin, Germany.
  • Neuhaus R; Department of Abdominal and Transplant Surgery, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, 13353 Berlin, Germany.
  • Karbasiyan M; Department of Medical Genetics, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, 13353 Berlin, Germany.
  • Gärtner B; Department of Microbiology, Saarland University Hospital, 66421 Homburg, Germany.
  • Anagnostopoulos I; Department of Pathology, Charité-Universitätsmedizin Berlin, Campus Mitte, 10117 Berlin, Germany.
  • Riess H; Department of Hematology, Charite University Hospitals, Campus Virchow-Klinikum, 13353 Berlin, Germany.
  • Trappe RU; Department of Internal Medicine II: Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany ; Department of Hematology, Charite University Hospitals, Campus Virchow-Klinikum, 13353 Berlin, Germany.
  • Oertel S; Global Medical Affairs Oncology, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.
J Immunol Res ; 2014: 264723, 2014.
Article em En | MEDLINE | ID: mdl-24741582
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polimorfismo Genético / Receptores de IgG / Anticorpos Monoclonais Murinos / Transtornos Linfoproliferativos / Antineoplásicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunol Res Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polimorfismo Genético / Receptores de IgG / Anticorpos Monoclonais Murinos / Transtornos Linfoproliferativos / Antineoplásicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunol Res Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Alemanha